Celldex Therapeutics, Inc. (CLDX - Free Report) will be reporting second-quarter 2016 results on Aug 8. Let’s see how things are shaping up for this Zacks Rank #3 (Hold) stock.
Factors at Play
Celldex, a development-stage, biopharmaceutical company, is focused on the development and commercialization of immunotherapies targeting cancer and other difficult-to-treat diseases.
The company earns revenues entirely from product development and licensing agreements, and contracts and grants. The company recognizes revenues under its clinical trial collaboration with Bristol-Myers Squibb Company (BMY - Free Report) for varlilumab.
Celldex has several early- and mid-stage candidates in its pipeline including glembatumumab vedotin (triple negative breast cancer - phase IIb; metastatic melanoma - phase II, squamous cell lung cancer – phase I/II; uveal melanoma and pediatric osteosarcoma); CDX-1401 (multiple solid tumors – phase II), CDX-301 (multiple indications – phase I) and CDX-014 (advanced renal cell carcinoma – phase I/II).
With no approved product in its portfolio, investor focus will remain on pipeline related updates.
Earnings Whispers?
Our proven model does not conclusively show that Celldex is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat earnings. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00% since the Most Accurate estimate is in line with the Zacks Consensus Estimate of a loss of 33 cents per share.
Zacks Rank: Celldex’s Zacks Rank #3 when combined with an ESP of 0.00% makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are a couple of health care companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
The Earnings ESP for Ionis Pharmaceuticals, Inc. (IONS - Free Report) is +10.71% and it carries a Zacks Rank #2. The company will release second-quarter results on Aug 9.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +300.00% and carries a Zacks Rank #2. It will be reporting second-quarter results on Aug 9.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Celldex Therapeutics, Inc. (CLDX - Free Report) will be reporting second-quarter 2016 results on Aug 8. Let’s see how things are shaping up for this Zacks Rank #3 (Hold) stock.
Factors at Play
Celldex, a development-stage, biopharmaceutical company, is focused on the development and commercialization of immunotherapies targeting cancer and other difficult-to-treat diseases.
The company earns revenues entirely from product development and licensing agreements, and contracts and grants. The company recognizes revenues under its clinical trial collaboration with Bristol-Myers Squibb Company (BMY - Free Report) for varlilumab.
Celldex has several early- and mid-stage candidates in its pipeline including glembatumumab vedotin (triple negative breast cancer - phase IIb; metastatic melanoma - phase II, squamous cell lung cancer – phase I/II; uveal melanoma and pediatric osteosarcoma); CDX-1401 (multiple solid tumors – phase II), CDX-301 (multiple indications – phase I) and CDX-014 (advanced renal cell carcinoma – phase I/II).
With no approved product in its portfolio, investor focus will remain on pipeline related updates.
Earnings Whispers?
Our proven model does not conclusively show that Celldex is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat earnings. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00% since the Most Accurate estimate is in line with the Zacks Consensus Estimate of a loss of 33 cents per share.
Zacks Rank: Celldex’s Zacks Rank #3 when combined with an ESP of 0.00% makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are a couple of health care companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
The Earnings ESP for Ionis Pharmaceuticals, Inc. (IONS - Free Report) is +10.71% and it carries a Zacks Rank #2. The company will release second-quarter results on Aug 9.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +300.00% and carries a Zacks Rank #2. It will be reporting second-quarter results on Aug 9.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMY - FREE
Get the latest research report on INCY - FREE
Get the latest research report on CLDX - FREE
Get the latest research report on IONS - FREE